Related Experiment Video
Updated: Mar 17, 2026
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Cannabidiol in Epilepsy: Restoring Locomotion and Seizure Control
John Ihayi Ogbu1, Thysia Mendes Rosa1, Antônio Sérgio Nakao de Aguiar1
1Laboratory of Pharmacology of Natural and Synthetic Products, Institute of Biological Sciences, Federal University of Goiás, Goiânia, GO, Brazil.
Cannabidiol (CBD) shows promise for managing epilepsy by reducing seizure severity and delaying onset. This phytocannabinoid demonstrates low toxicity and multitarget mechanisms, offering potential neuroprotection and improved outcomes for treatment-resistant epilepsy patients.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Epilepsy affects millions globally, with a significant portion exhibiting treatment resistance.
- Seizures and motor deficits are primary concerns in epilepsy management.
- Cannabidiol (CBD) is being investigated for its therapeutic potential in epilepsy.
Purpose of the Study:
- To review the effects and mechanisms of Cannabidiol (CBD) in epilepsy models.
- To explore CBD's therapeutic potential for seizure control and motor outcomes.
- To investigate CBD's biological targets using network pharmacology and molecular modeling.
Main Methods:
- Systematic review of studies on CBD in animal and human epilepsy models.
- Application of network pharmacology to identify CBD's biological targets.
- Molecular modeling to analyze CBD-protein interactions.
Main Results:
- CBD demonstrates low toxicity and good tolerability with minimal impact on motor function.
- Evidence indicates CBD can prolong seizure onset time and reduce seizure severity.
- CBD modulates multiple targets, including endocannabinoid signaling, neurotransmission, inflammation, and metabolic pathways.
Conclusions:
- CBD exhibits potential as an antiepileptic agent through multitarget mechanisms.
- Its neuroprotective effects are linked to regulating key biological pathways.
- Further research into CBD's mechanisms could advance epilepsy treatment strategies.
More Related Videos
09:49Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
Published on: June 29, 2022
09:46Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus
Published on: March 8, 2015
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...